AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
Buy more, save more
Total Price
$70
For research & laboratory use only. Not for human consumption.
Half-Life
30-60 minutes
Administration Route
Subcutaneous injection
Targeted Fat Breakdown
Activates lipolysis without stimulating IGF-1 or growth
No Glucose Impact
Does not affect blood sugar or insulin sensitivity
Growth Factor Activity
Retains bone-protective effects of HGH C-terminal fragment
Effect Profile
Fat Loss
Hunger Control
Metabolic Health
Energy
Effect Timeline
Lipolytic signalling active; fat cell metabolism increases
Stubborn fat deposits begin mobilising
Visible reduction in body fat %, especially peripherally
Sustained fat loss without lean mass loss confirmed
Start — Week 2
Lipolytic signalling active; fat cell metabolism increases
Week 4
Stubborn fat deposits begin mobilising
Week 8
Visible reduction in body fat %, especially peripherally
Week 12
Sustained fat loss without lean mass loss confirmed
Mechanism of Action
Scientific Research
Obesity Reviews (2006)
Product FAQs
Stacks Well With
Related Products
HGH Fragment 176-191
C-terminal fragment of human growth hormone (amino acids 176-191) with potent lipolytic activity. Studied for adipose reduction without the growth-promoting or
HGH (Somatropin) 191aa
Recombinant 191-amino acid human growth hormone identical to pituitary-derived GH. Used as the reference standard in GH axis research for body composition
Lipo-C
Lipotropic injection combining methionine, inositol, and choline (MIC). Promotes hepatic fat metabolism, supports bile production, and is used in weight